Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats

Drug Metabolism and Disposition

Volumn 30, Issue 5, 2002, Pages 479-482

  Savolainen, Jouko ^a,b   Edwards, Jeffrey E ^a   Morgan, Michael E ^a   McNamara, Patrick J ^a   Anderson, Bradley D ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 2',3' DIDEOXYPURINE; ADENOSINE DEAMINASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDANOSINE; ELACRIDAR; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; NELFINAVIR; PRODRUG; PROTEIN INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG PENETRATION; DRUG UPTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ACRIDINES; ANIMALS; ANTI-HIV AGENTS; BRAIN; DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; ISOQUINOLINES; MALE; NELFINAVIR; P-GLYCOPROTEIN; PRODRUGS; PURINE NUCLEOSIDES; RATS; RATS, SPRAGUE-DAWLEY; TETRAHYDROISOQUINOLINES;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0036237761     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.5.479     Document Type: Article

References (29)

1. Uptake kinetics of 2′,3′-dideoxyinosine into brain and cerebrospinal fluid of rats: Intravenous infusion studies
2. HIV-1 associated CNS disease in infants and children
3. Central nervous system infections - AIDS dementia complex
4. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection
5. Antiretroviral therapy in adults - Updated recommendations of the international AIDS society-USA panel
6. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes
7. Peptide transport by the multidrug resistance protein MRPI
8. Probenecid enhances central nervous system uptake of 2′3′-dideoxyinosine by inhibiting cerebrospinal fluid efflux
9. Azidothymidine associated with bone marrow failure in the acquired immunodeficiency syndrome (AIDS)
10. Pharmacokinetics of 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine in patients with severe human immunodeficiency virus infection
11. Distribution and inhibition of adenosine deaminase in tissues of man, rat, and mouse
12. Parallel functional and immunological detection of human multidrug resistance proteins, P-glycoprotein and MRPI
13. Expression of multidrug resistance-associated protein (MRP) on brain microvessel endothelial cells
14. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative
15. Antiretroviral therapy of HIV-1 infection: Established treatment strategies and new therapeutic options
16. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
17. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat
18. Dementia in AIDS patients: Incidence and risk factors. Multicenter AIDS cohort study
19. Central nervous system targeting of 2′,3′-dideoxyinosine via adenosine deaminase-activated 6-halo-dideoxypurine prodrugs
20. Escherichia coli mediated biosynthesis and in vitro anti-HIV activity of lipophilic 6-halo-2′,3′-dideoxypurine nucleosides
21. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor
22. Neuroscience research in AIDS
23. Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease
24. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins
25. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDRI and MRPI but retain antiviral efficacy in cell lines expressing these transporters
26. Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex
27. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GF918
28. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: Structural identification, levels in plasma, and antiviral activities